{"title":"lncRNA PANDAR在乳腺癌细胞增殖中的调控作用。","authors":"Qinnuan Sun, Xiumei Wang","doi":"10.2478/abm-2021-0035","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer represents the second most deadly malignancy in women, and long noncoding RNAs (lncRNAs) have crucial functions in its development.</p><p><strong>Objective: </strong>To investigate effects of the promoter of <i>CDKN1A</i> antisense DNA damage-activated RNA (<i>PANDAR</i>) on epithelial-mesenchymal transition (EMT) in breast cancer cells and their proliferation.</p><p><strong>Methods: </strong>lncRNAs potentially regulating the transcriptional activity of the E-cadherin (E-cad, an epithelial cell marker) gene promoter were screened using a dual-luciferase reporter assay. <i>PANDAR</i> was overexpressed in Michigan cancer foundation 7 (MCF-7) breast cancer cells. E-cad and N-cadherin (N-cad, a mesenchymal cell marker) levels were detected by immunoblotting. Cell viability was assessed using a cell counting kit-8.</p><p><strong>Results: </strong><i>PANDAR</i> and <i>TCONS00068220</i>/<i>LOC105375819</i> conservatively regulated the promoter activity of <i>E-cad</i>. <i>PANDAR</i> overexpression in MCF-7 inhibited E-cad expression, but upregulated N-cad. The enhanced expression of <i>PANDAR</i> promoted cell proliferation.</p><p><strong>Conclusion: </strong><i>PANDAR</i> is a key transcriptional repressor of <i>E-cad</i> and has regulatory effects on the promotion of cell proliferation. <i>PANDAR</i> is an oncogene in breast cancer, potentially facilitating the EMT process and promoting cell proliferation.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321221/pdf/","citationCount":"0","resultStr":"{\"title\":\"Regulatory roles of lncRNA <i>PANDAR</i> in breast cancer cell proliferation.\",\"authors\":\"Qinnuan Sun, Xiumei Wang\",\"doi\":\"10.2478/abm-2021-0035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer represents the second most deadly malignancy in women, and long noncoding RNAs (lncRNAs) have crucial functions in its development.</p><p><strong>Objective: </strong>To investigate effects of the promoter of <i>CDKN1A</i> antisense DNA damage-activated RNA (<i>PANDAR</i>) on epithelial-mesenchymal transition (EMT) in breast cancer cells and their proliferation.</p><p><strong>Methods: </strong>lncRNAs potentially regulating the transcriptional activity of the E-cadherin (E-cad, an epithelial cell marker) gene promoter were screened using a dual-luciferase reporter assay. <i>PANDAR</i> was overexpressed in Michigan cancer foundation 7 (MCF-7) breast cancer cells. E-cad and N-cadherin (N-cad, a mesenchymal cell marker) levels were detected by immunoblotting. Cell viability was assessed using a cell counting kit-8.</p><p><strong>Results: </strong><i>PANDAR</i> and <i>TCONS00068220</i>/<i>LOC105375819</i> conservatively regulated the promoter activity of <i>E-cad</i>. <i>PANDAR</i> overexpression in MCF-7 inhibited E-cad expression, but upregulated N-cad. The enhanced expression of <i>PANDAR</i> promoted cell proliferation.</p><p><strong>Conclusion: </strong><i>PANDAR</i> is a key transcriptional repressor of <i>E-cad</i> and has regulatory effects on the promotion of cell proliferation. <i>PANDAR</i> is an oncogene in breast cancer, potentially facilitating the EMT process and promoting cell proliferation.</p>\",\"PeriodicalId\":8501,\"journal\":{\"name\":\"Asian Biomedicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321221/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Biomedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/abm-2021-0035\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/abm-2021-0035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Regulatory roles of lncRNA PANDAR in breast cancer cell proliferation.
Background: Breast cancer represents the second most deadly malignancy in women, and long noncoding RNAs (lncRNAs) have crucial functions in its development.
Objective: To investigate effects of the promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR) on epithelial-mesenchymal transition (EMT) in breast cancer cells and their proliferation.
Methods: lncRNAs potentially regulating the transcriptional activity of the E-cadherin (E-cad, an epithelial cell marker) gene promoter were screened using a dual-luciferase reporter assay. PANDAR was overexpressed in Michigan cancer foundation 7 (MCF-7) breast cancer cells. E-cad and N-cadherin (N-cad, a mesenchymal cell marker) levels were detected by immunoblotting. Cell viability was assessed using a cell counting kit-8.
Results: PANDAR and TCONS00068220/LOC105375819 conservatively regulated the promoter activity of E-cad. PANDAR overexpression in MCF-7 inhibited E-cad expression, but upregulated N-cad. The enhanced expression of PANDAR promoted cell proliferation.
Conclusion: PANDAR is a key transcriptional repressor of E-cad and has regulatory effects on the promotion of cell proliferation. PANDAR is an oncogene in breast cancer, potentially facilitating the EMT process and promoting cell proliferation.
期刊介绍：
Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries
Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
